Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Cancer Invest. 2013 Mar;31(3):197-205. doi: 10.3109/07357907.2013.775294.
Non-small cell lung cancer (NSCLC) is found worldwide with high incidence and poor prognoses. Nowadays, insights in the interaction between tumors and immune system have led to the development of immunotherapy as a fundamentally new concept for the treatment of NSCLC. Adoptive cell transfer represents an important advancement in cancer immunotherapy such as cytokine-induced killer and γδ T-cells. Recent clinical research studies provide evidence for the positive effects of adoptive immunotherapy, which is probably associated with levels of cytokines, cell doses, and immune microenvironment. This review summarizes the current condition of adoptive immunotherapy in NSCLC and the long-standing confusion in this field.
非小细胞肺癌（NSCLC）在全球范围内发病率高，预后差。如今，人们对肿瘤与免疫系统相互作用的认识促使免疫疗法作为治疗 NSCLC 的一种全新概念得到发展。过继细胞转移是癌症免疫疗法的重要进展，如细胞因子诱导的杀伤细胞和 γδ T 细胞。最近的临床研究提供了过继免疫疗法的积极效果的证据，这可能与细胞因子水平、细胞剂量和免疫微环境有关。本文综述了 NSCLC 过继免疫疗法的现状及该领域长期存在的困惑。
